Genus PLC - Basingstoke, Hampshire-based company that sells products made using biotechnology to cattle and pig farmers - Updates on its porcine reproductive and respiratory syndrome virus resistance programme, as part of capital markets event on Tuesday. Says in most recent trial, 40 animals infected with two prevalent types of the PRRS virus, were tested, with the trial demonstrating the gene-edited pigs were 100% resistant to both types of the PRRS virus, confirming previous academic findings. In the next phase of trials, Genus says it will be evaluating whether PRRSv resistance was preserved across generations by breeding and testing the offspring of the first generation of edited pigs. These trials will be included as part of the submissions to the US Food & Drug Administration as part of the regulatory review process, it adds.
Current stock price: 4,986.00 pence
Year-to-date change: up 16%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Genus (GNS)